Risk organ + LCH gets the one-two punch?

摘要

In this issue of Blood, Donadieu et al1 present what may be the most encouraging data to date on a group of patients with Langerhans cell histiocytosis (LCH), which historically has poor disease-free survival and poor overall survival.